Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues

Medical treatment of meningiomas is reserved for cases in which surgery and radiotherapy have failed. Given that a high percentage of meningiomas express somatostatin receptors, treatment with somatostatin analogues has been proposed. In addition, these medications have been shown to have an antiproliferative and antiangiogenic effect in vitro. To date, very few cases with clinical response and none with radiological response have been described. The case described here is the first to report a radiological response. A 76-year-old Caucasian male was first diagnosed with unresectable meningioma at age 47. The patient experienced multiple recurrences and underwent three surgeries and radiotherapy over the years from the initial diagnosis. Despite treatment, the disease continued its progression. Based on an Octreoscan positive for tumour uptake, therapy with extended-release somatostatin analogues was started. Although no clinical neurological improvement was observed, magnetic resonance imaging scans revealed a discreet but continuous radiological response over time. After >2 years of continuous administration of lanreotide, the patient remains progression free. In highly selected cases, somatostatin analogue treatment for meningioma may be benD ow nl oa de d by : 54 .1 91 .4 0. 80 9 /1 7/ 20 17 9 :5 1: 30 A M Case Rep Oncol 2016;9:520–525 DOI: 10.1159/000448212 © 2016 The Author(s). Published by S. Karger AG, Basel www.karger.com/cro Ortolá Buigues et al.: Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues 521 eficial. Based on our findings, treatment with somatostatin analogues should be maintained longer than previously described before evaluating treatment response. © 2016 The Author(s) Published by S. Karger AG, Basel